Jones Day is a global law firm with more than 2,500 lawyers across five continents. The Firm is distinguished by a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
During its October 5–8, 2015, meetings, the Pharmacovigilance Risk Assessment Committee ("PRAC") discussed three ongoing referrals on SGLT2 inhibitors, human papillomavirus ("HPV") vaccines, and Tysabri.
European UnionFood, Drugs, Healthcare, Life Sciences
During its October 5–8, 2015, meetings, the Pharmacovigilance
Risk Assessment Committee ("PRAC") discussed three ongoing referrals on SGLT2 inhibitors, human papillomavirus ("HPV")
vaccines, and Tysabri. The PRAC did not initiate or conclude
a safety referral. A record of the discussions will be provided in
the minutes of the meeting, which will be published following the
next PRAC meeting in November 2015.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
